US 11,795,209 B2
PVRIG polypeptides and methods of treatment
Mark White, Antioch, CA (US); Sandeep Kumar, San Bruno, CA (US); Christopher Chan, South San Francisco, CA (US); Spencer Liang, San Mateo, CA (US); Lance Stapleton, Oakland, CA (US); Andrew W. Drake, Mountain View, CA (US); Yosi Gozlan, Tel Aviv (IL); Ilan Vaknin, Tel Aviv (IL); Shirley Sameah-Greenwald, Kfar Saba (IL); Liat Dassa, Tel Aviv (IL); Zohar Tiran, Oranit (IL); Gad S. Cojocaru, Tel Aviv (IL); Amir Toporik, Binyamina (IL); Yossef Kliger, Rishon le Zion (IL); Ofer Levy, Moshav Mesilat Zion Doar Na Shimson (IL); Arthur Machlenkin, Tel Aviv (IL); Sergey Nemzer, Ranaana (IL); Yair Benita, Tel Aviv (IL); and Amit Novik, Binyamina (IL)
Assigned to COMPUGEN LTD., Holon (IL)
Filed by Compugen Ltd., Holon (IL)
Filed on Jan. 28, 2020, as Appl. No. 16/775,133.
Application 16/775,133 is a continuation of application No. 15/048,975, filed on Feb. 19, 2016, granted, now 10,550,173.
Claims priority of provisional application 62/141,168, filed on Mar. 31, 2015.
Claims priority of provisional application 62/118,235, filed on Feb. 19, 2015.
Prior Publication US 2020/0385445 A1, Dec. 10, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/53 (2006.01); C07K 16/10 (2006.01); G01N 33/574 (2006.01); G01N 33/50 (2006.01); C12N 15/113 (2010.01); C07K 16/28 (2006.01); C07K 7/06 (2006.01); C07K 14/705 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/1009 (2013.01) [C07K 7/06 (2013.01); C07K 14/70503 (2013.01); C07K 16/2803 (2013.01); C07K 16/2818 (2013.01); C12N 15/1138 (2013.01); G01N 33/502 (2013.01); G01N 33/505 (2013.01); G01N 33/5011 (2013.01); G01N 33/574 (2013.01); A61K 2039/507 (2013.01); C07K 2317/74 (2013.01); C07K 2319/30 (2013.01); C12N 2310/14 (2013.01); G01N 2333/70596 (2013.01); G01N 2500/02 (2013.01); G01N 2500/10 (2013.01); Y02A 50/30 (2018.01)] 15 Claims
 
1. A method of screening for anti-PVRIG antibodies and fragments thereof, wherein the method comprises:
i) providing a first cell comprising an exogenous recombinant nucleic acid encoding a human PVRIG polypeptide, wherein the first cell expresses the human PVRIG polypeptide;
ii) contacting the first cell with a second cell comprising another exogenous recombinant nucleic acid encoding a human PVRL2 polypeptide, wherein the second cell expresses the human PVRL2 polypeptide, in the presence of a candidate agent comprising an antibody or fragment thereof; and
iii) determining whether the first cell binds to the second cell as an indication of whether the candidate agent comprising an antibody or fragment thereof comprises an anti-PVRIG antibody or a fragment thereof that inhibits the binding of PVRIG with PVRL2.